DE102018215551A1 - Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten - Google Patents

Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten Download PDF

Info

Publication number
DE102018215551A1
DE102018215551A1 DE102018215551.8A DE102018215551A DE102018215551A1 DE 102018215551 A1 DE102018215551 A1 DE 102018215551A1 DE 102018215551 A DE102018215551 A DE 102018215551A DE 102018215551 A1 DE102018215551 A1 DE 102018215551A1
Authority
DE
Germany
Prior art keywords
primary
cells
carcinoma
virus
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102018215551.8A
Other languages
German (de)
English (en)
Inventor
Cornelia Hardt
Michael Bergerhausen
Hilal Bhat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abalos Therapeutics GmbH
Original Assignee
Virolutions Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virolutions Biotech GmbH filed Critical Virolutions Biotech GmbH
Priority to DE102018215551.8A priority Critical patent/DE102018215551A1/de
Priority to AU2019340845A priority patent/AU2019340845B2/en
Priority to EP21205198.1A priority patent/EP4019533A1/en
Priority to SG11202101970UA priority patent/SG11202101970UA/en
Priority to IL281299A priority patent/IL281299B2/en
Priority to BR112021004451-5A priority patent/BR112021004451A2/pt
Priority to MX2021002937A priority patent/MX2021002937A/es
Priority to ES19782905T priority patent/ES2908854T3/es
Priority to DK19782905.4T priority patent/DK3694868T3/da
Priority to CN201980074560.2A priority patent/CN112996802B/zh
Priority to KR1020217010631A priority patent/KR20210057782A/ko
Priority to PCT/EP2019/074307 priority patent/WO2020053324A1/en
Priority to EP19782905.4A priority patent/EP3694868B1/en
Priority to US17/275,967 priority patent/US12129281B2/en
Priority to CN202510196120.1A priority patent/CN120158432A/zh
Priority to NZ774584A priority patent/NZ774584B2/en
Priority to CA3111305A priority patent/CA3111305A1/en
Priority to JP2021514594A priority patent/JP7583448B2/ja
Publication of DE102018215551A1 publication Critical patent/DE102018215551A1/de
Priority to PH12021550424A priority patent/PH12021550424A1/en
Priority to CL2021000592A priority patent/CL2021000592A1/es
Priority to ZA2021/01833A priority patent/ZA202101833B/en
Priority to US18/927,732 priority patent/US20250122244A1/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE102018215551.8A 2018-09-12 2018-09-12 Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten Withdrawn DE102018215551A1 (de)

Priority Applications (22)

Application Number Priority Date Filing Date Title
DE102018215551.8A DE102018215551A1 (de) 2018-09-12 2018-09-12 Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
EP19782905.4A EP3694868B1 (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants
PCT/EP2019/074307 WO2020053324A1 (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants
SG11202101970UA SG11202101970UA (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants
IL281299A IL281299B2 (en) 2018-09-12 2019-09-12 Method for creating an arena virus directed against a tumor and for creating mutants of the virus
BR112021004451-5A BR112021004451A2 (pt) 2018-09-12 2019-09-12 método para produção de um arenavírus antitumoral, bem como mutantes de arenavírus
MX2021002937A MX2021002937A (es) 2018-09-12 2019-09-12 Metodo para producir un arenavirus antitumoral asi como mutantes de arenavirus.
ES19782905T ES2908854T3 (es) 2018-09-12 2019-09-12 Método para producir un arenavirus antitumoral así como mutantes de arenavirus
US17/275,967 US12129281B2 (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants
EP21205198.1A EP4019533A1 (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants
KR1020217010631A KR20210057782A (ko) 2018-09-12 2019-09-12 항종양 아레나바이러스 및 아레나바이러스 돌연변이체의 제조 방법
AU2019340845A AU2019340845B2 (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants
CN201980074560.2A CN112996802B (zh) 2018-09-12 2019-09-12 用于制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体
DK19782905.4T DK3694868T3 (da) 2018-09-12 2019-09-12 Fremgangsmåde for at fremstille en antitumoral arenavirus såvel som arenavirusmutanter
CN202510196120.1A CN120158432A (zh) 2018-09-12 2019-09-12 用于制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体
NZ774584A NZ774584B2 (en) 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants
CA3111305A CA3111305A1 (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants
JP2021514594A JP7583448B2 (ja) 2018-09-12 2019-09-12 抗腫瘍アレナウイルスおよびアレナウイルス変異体を生産するための方法
PH12021550424A PH12021550424A1 (en) 2018-09-12 2021-03-01 Method for producing an antitumoral arenavirus as well as arenavirus mutants
CL2021000592A CL2021000592A1 (es) 2018-09-12 2021-03-10 Método para producir un arenavirus antitumoral así como mutantes de arenavirus
ZA2021/01833A ZA202101833B (en) 2018-09-12 2021-03-18 Method for producing an antitumoral arenavirus as well as arenavirus mutants
US18/927,732 US20250122244A1 (en) 2018-09-12 2024-10-25 Method for producing an antitumoral arenavirus as well as arenavirus mutants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102018215551.8A DE102018215551A1 (de) 2018-09-12 2018-09-12 Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten

Publications (1)

Publication Number Publication Date
DE102018215551A1 true DE102018215551A1 (de) 2020-03-12

Family

ID=68138008

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102018215551.8A Withdrawn DE102018215551A1 (de) 2018-09-12 2018-09-12 Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten

Country Status (18)

Country Link
US (2) US12129281B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019533A1 (cg-RX-API-DMAC7.html)
JP (1) JP7583448B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210057782A (cg-RX-API-DMAC7.html)
CN (2) CN120158432A (cg-RX-API-DMAC7.html)
AU (1) AU2019340845B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004451A2 (cg-RX-API-DMAC7.html)
CA (1) CA3111305A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000592A1 (cg-RX-API-DMAC7.html)
DE (1) DE102018215551A1 (cg-RX-API-DMAC7.html)
DK (1) DK3694868T3 (cg-RX-API-DMAC7.html)
ES (1) ES2908854T3 (cg-RX-API-DMAC7.html)
IL (1) IL281299B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002937A (cg-RX-API-DMAC7.html)
PH (1) PH12021550424A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101970UA (cg-RX-API-DMAC7.html)
WO (1) WO2020053324A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101833B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121022940A (zh) * 2025-10-30 2025-11-28 山东第一医科大学(山东省医学科学院) 一种抑制塔姆德病毒感染的方法及tcp1抑制剂的用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022180203A1 (en) 2021-02-26 2022-09-01 Abalos Therapeutics Gmbh New virus particles for therapeutic purposes
IL326615A (en) * 2023-08-31 2026-04-01 Abalos Therapeutics Gmbh Virus particles with improved entry into tumor cells
CN117867030A (zh) * 2024-01-15 2024-04-12 苏州健雄职业技术学院 小鼠肺癌细胞系cmt167荧光素酶稳转细胞株的构建与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461A1 (de) * 2004-07-16 2006-02-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
WO2016166285A1 (de) * 2015-04-17 2016-10-20 Lang Karl Sebastian Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
CN102439146A (zh) 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
WO2012093340A2 (en) * 2011-01-07 2012-07-12 Bioscience Slovakia Viral diagnostics
JP6162818B2 (ja) * 2012-12-12 2017-07-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド 脳癌の治療のための組成物及び方法
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CN110167586B (zh) * 2016-11-04 2024-01-30 霍欧奇帕生物科技有限公司 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461A1 (de) * 2004-07-16 2006-02-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
WO2016166285A1 (de) * 2015-04-17 2016-10-20 Lang Karl Sebastian Arenaviren zur anwendung bei der behandlung und/oder vorbeugung von tumoren sowie verfahren zur herstellung von arenaviren mit (verbesserten) tumorregressiven eigenschaften

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121022940A (zh) * 2025-10-30 2025-11-28 山东第一医科大学(山东省医学科学院) 一种抑制塔姆德病毒感染的方法及tcp1抑制剂的用途

Also Published As

Publication number Publication date
MX2021002937A (es) 2021-07-16
ZA202101833B (en) 2022-10-26
SG11202101970UA (en) 2021-03-30
WO2020053324A1 (en) 2020-03-19
EP3694868A1 (en) 2020-08-19
ES2908854T3 (es) 2022-05-04
US12129281B2 (en) 2024-10-29
JP7583448B2 (ja) 2024-11-14
EP3694868B1 (en) 2021-11-03
NZ774584A (en) 2024-09-27
IL281299B2 (en) 2025-07-01
CN112996802A (zh) 2021-06-18
CN120158432A (zh) 2025-06-17
IL281299B1 (en) 2025-03-01
US20250122244A1 (en) 2025-04-17
EP4019533A1 (en) 2022-06-29
CN112996802B (zh) 2025-03-11
CL2021000592A1 (es) 2021-09-10
KR20210057782A (ko) 2021-05-21
US20220033445A1 (en) 2022-02-03
JP2022500054A (ja) 2022-01-04
IL281299A (en) 2021-04-29
AU2019340845B2 (en) 2026-01-29
CA3111305A1 (en) 2020-03-19
BR112021004451A2 (pt) 2021-06-01
PH12021550424A1 (en) 2021-09-20
DK3694868T3 (da) 2022-02-07
AU2019340845A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7023929B2 (ja) キメラポックスウイルス組成物及びその使用
DE69634904T2 (de) Negativstrand rna virus mit selbständiger replikationsaktivität
SG10202107138TA (en) Oncolytic viral vectors and uses thereof
US20250122244A1 (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
EP3283104B1 (de) Arenaviren zur anwendung bei der behandlung eines tumors beim menschen
CN107083385A (zh) 产热的miRNA调节剂
US20200206314A1 (en) Hsv vectors for delivery of nt3 and treatment of cipn
US20250340904A1 (en) Compositions and therapeutic methods of microrna gene delivery
KR20170103697A (ko) 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물
CA3109740A1 (en) Blood-brain barrier permeable aptamer and application thereof
US11524047B2 (en) Pharmaceutical compositions for preventing or treating pulmonary metastasis of cancer including CHI3L1 inhibitor as active ingredient
EP2978402B1 (de) Stabilisiertes polyribonucleotid codierend für ein elastisches faserprotein
DE202022003066U1 (de) Genetische Modifikation von Säugerzellen zur Verleihung von Resistent gegen CSF1R-Antagonisten
US10335481B2 (en) Gene-modified measles virus for tumor treatment use
DE112018002302T5 (de) Chimärer Antigenrezeptor von Anti-Human-CD19-Antigen und dessen Anwendung
JP2023549674A (ja) 癌の処置用の免疫調節治療薬としての免疫細胞におけるsrc-3の標的化
DE60036929T2 (de) Gentherapeutika
RU2812046C2 (ru) Способ продуцирования аренавируса, а также мутантов аренавируса с противоопухолевыми свойствами
US9546354B2 (en) Z cells activated by zinc finger-like protein and uses thereof in cancer treatment
WO2023230523A1 (en) Modulation of satellite cell polarity and asymmetric cell division
HUT50636A (en) Process for influencing cell-relations resistant to lymphokines by applying double-filament rna-s

Legal Events

Date Code Title Description
R082 Change of representative

Representative=s name: SCHIWECK WEINZIERL KOCH PATENTANWAELTE PARTNER, DE

R163 Identified publications notified
R081 Change of applicant/patentee

Owner name: ABALOS THERAPEUTICS GMBH, DE

Free format text: FORMER OWNER: LANG, KARL SEBASTIAN, PROF. DR., 45149 ESSEN, DE

R082 Change of representative

Representative=s name: SCHIWECK WEINZIERL KOCH PATENTANWAELTE PARTNER, DE

R081 Change of applicant/patentee

Owner name: ABALOS THERAPEUTICS GMBH, DE

Free format text: FORMER OWNER: VIROLUTIONS BIOTECH GMBH, 45130 ESSEN, DE

R005 Application deemed withdrawn due to failure to request examination